3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
28
Rectal Neoplasms
6
Colonic Neoplasms
6
Stomach Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Neutropenia
2
Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Advanced Solid Tumors
2
mCRC
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Sarcoma, Ewing
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Microsatellite-stable Colorectal Cancer
1
Metastatic Gastric Adenocarcinoma
1
Lung Neoplasms
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric and Gastroesophageal Junction Adenocarcinoma
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Interventions
Fluorouracil
16
Oxaliplatin
14
Nivolumab
14
Leucovorin
13
pembrolizumab
9
Paclitaxel
9
Capecitabine
9
Radiotherapy
6
Radiation
6
durvalumab
5
Taxes
5
Irinotecan
5
Cisplatin
5
Trastuzumab
4
Specimen Handling
4
Drug Therapy
4
Carboplatin
4
tremelimumab
3
dehydroftorafur
3
Ramucirumab
3
Magnetic Resonance Spectroscopy
3
Folfox protocol
3
Endoscopy
3
Docetaxel
3
Biopsy
3
zimberelimab
2
zanidatamab
2
trastuzumab deruxtecan
2
tislelizumab
2
futibatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
trifluridine tipiracil drug combination
×
1 year
×
Clear all
NCT06356311
2026-02-27
TroFuse-015
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
450 enrolled